Molecular Analysis of Oxacillinase Genes in MDR Strain of Acinetobacter baumannii Isolated in Clinical Samples from North India
DOI:
https://doi.org/10.52783/jns.v14.3432Keywords:
Molecular, Oxacillinase, Genes, MDR, Acinetobacter baumanniiAbstract
Background: Acinetobacter baumannii is a ubiquitous coccobacillus which is currently a topic of great concern due to its high level of drug resistance to almost all classes of antimicrobials. Due to this it results in high level of morbidity and mortality in hospitalizedpatients especially in critical care areas. This opportunistic pathogen in short span of time has acquired high level of resistance against carbapenem which are one of the last resorts in our antimicrobial arsenal.
Aim and Objective: To study the molecular analysis of oxacillinase genes in MDR strain of Acinetobacter baumannii isolated in clinical samples from North India.
Material and Methods: Clinical samples received for bacterial culture and antimicrobial sensitivity testing were inoculated and incubated for 24-48 hours at 37°C. For blood culture incubation was done for 5 days in blood culture bottle. Bacterial identification and antimicrobial sensitivity were done by Vitek®2, bioMérieux. Antimicrobial Sensitivity of A. baumanniiisolated was recorded and multi drug resistant isolates were preserved for Polymerase chain reaction(PCR) to detect the presence ofbeta lactam OxacillinaseblaOXA 51 and blaOXA58 genes.
Results: A total of 2644 samples were processed during the study period from 30th April,2022 to 20th October,2024. 920 samples were culture positive. Out of 920 bacterial isolates, 88 were A. baumannii and 84 out of these were Carbapenem Resistant A. baumannii(CRAB). 30 CRAB isolates were selected for PCR and all showed presence of blaOXA 51 gene while none of the isolates harbored blaOXA 58 gene.
Conclusions: There is an increased isolation rate of A. baumannii from clinical samples and more than 95% isolates of A. baumannii are CRAB. All the CRAB isolates tested by PCR showed presence of blaOXA 51 gene and none had the presence of blaOXA 58 gene. Management of A. baumannii infections is a challenge. In the current scenario proper implementation of Hospital Infection Control policies and adherence to antimicrobial stewardship policies as preventive strategies should be our priority.
Downloads
Metrics
References
Adewoyin MA, Okoh AI. The natural environment as a reservoir of pathogenic and non-pathogenic Acinetobacter species. Rev Environ Health. 2018;33:265–272.
García-Patiño, M.G.; García-Contreras, R.; Licona-Limón, P. The Immune Response against Acinetobacter baumannii, an Emerging Pathogen in Nosocomial Infections. Front Immunol. 2017, 12, 8–441. [Google Scholar] [CrossRef] [PubMed]
Wong, D. et al. Clinical and pathophysiological overview of Acinetobacter infections: a century of
challenges. Clin. Microbiol. Rev. 30, 409–447 (2017).
Seleim, S. M., Mostafa, M. S., Ouda, N. H., and Shash, R. Y. (2022). The role of PmrCAB genes in colistin-resistant Acinetobacter baumannii. Sci. Rep. 12, 20951. doi: 10.1038/s41598-022-25226-x
Anand, K. P., & Neha, T. (2023). Detection of methicillin-resistant Staphylococcus aureus and determination of minimum inhibitory concentration of vancomycin for Staphylococcus aureus. ISSN: 2320-8708, 11(1).
Docquier, J.D.; Mangani, S. Structure-function relationships of class D carbapenemases. Curr. Drug Targets 2016, 17, 1061–1071.
[CrossRef] [PubMed]
Girlich, D.; Poirel, L.; Nordmann, P. First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter
baumannii isolate. Antimicrob. Agents Chemother. 2010, 54, 578–579. [CrossRef] [PubMed]
Turton JF, Kaufmann ME, Gill MJ, Pike R, Scott PT, Fishbain J, et al. Comparison of Acinetobacter baumannii isolates from the United Kingdom and the United States that were associated with repatriated casualties of
the Iraq conflict. J Clin Microbiol 2006; 44:2630-4; PMID:16825400; http://dx.doi.org/10.1128/JCM.
-06
World Health Organization. Global priority list of antibiotic-resistant bacteria to guide researach,
discovery and development of new antibiotics. WHO http://www.who.int/medicines/publications/WHO-PPLShort_Summary_25Feb-ET_NM_WHO.pdf?ua=1(2017)
Clinical and Laboratory Standards Institute. M100: Performance Standards for Antimicrobial Susceptibility Testing, 29th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2019.
Fadana V, Thomas T, von Knorring N. Retrospective analysis of Vitek®2 performance compared to manual broth micro-dilution for colistin susceptibility testing of Acinetobacter baumanniicomplex isolates in South Africa. Afr J Lab Med. 2022 Feb 28;11(1):1597. doi: 10.4102/ajlm.v11i1.1597. PMID: 35282395; PMCID: PMC8905463.
Jean, S.S.; Hsueh, P.R. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens. Expert Opin. Pharmacother. 2011, 12, 2145–2148. [CrossRef]
Gordon, N.C.; Wareham, D.W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J. Antimicrob. Chemother. 2009, 63, 775–780. [CrossRef] [PubMed]
Gur, D.; Korten, V.; Unal, S.; Deshpande, L.M.; Castanheira, M. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: Report from the Turkish SENTRY. J. Med. Microbiol. 2008, 57, 1529–1532. [CrossRef] [PubMed]
Djahmi, N.; Dunyach-Remy, C.; Pantel-Dekhil, M.; Sotto, A.; Lavigne, J.P. Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries. Biomed. Res. Int. 2014, 2014, 305784. [CrossRef]
Andriamanantena TS, Ratsima E, Rakotonirina HC, Randrianirina F, Ramparany L, Carod JF, et al Dissemination of multidrug resistant Acinetobacter baumannii in various hospitals of Antananarivo Madagascar Ann Clin MicrobiolAntimicrob. 2010;9:17
Rahman, M. & Ahmed, S.. (2020). Prevalence of colistin resistance gene mcr-1 in clinical Isolates Acinetobacter Baumannii from India. International Journal of Infectious Diseases. 101. 81. 10.1016/j.ijid.2020.09.238.
Dey, A., Yadav, M., Kumar, D., Dey, A. K., Samal, S., Tanwar, S., et al. (2022). A combination therapy strategy for treating antibiotic resistant biofilm infection using guanidinium derivative and nanoparticulate Ag(0) derived hybrid gel conjugate. Chem. Sci. 13, 10103–10118. doi: 10.1039/D2SC02980D
Melo, M.C.R., Maasch, J.R.M.A. & de la Fuente-Nunez, C. Accelerating antibiotic discovery through artificial intelligence. Commun Biol 4, 1050 (2021). https://doi.org/10.1038/s42003-021-02586-0
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
